New Law Requires Hospitals to Publish Prices for Procedures

Thanks to a new law that went into effect on January 1, 2019, hospitals are now required to publish the prices of their procedures. The hospital’s price list must be made public, published online and updated each year, according to a story in Newsweek. The new law also applies to rehabilitation facilities, psychiatric hospitals and…

Read More

The VA Ignored Millions Earmarked for Veteran Suicide Prevention

Preventing veterans from committing suicide was named the “highest clinical priority” by the Veterans Administration, yet VA officials still failed to spend the $17.7 million in the suicide prevention budget for fiscal year 2018, according to a story in Time Magazine. A report published in November 2018 by the U.S. Government Accountability Office (GAO) found…

Read More

Former CEO of Insys to Plead Guilty in Opioid-Kickback Scheme

In late December of 2018, federal prosecutors announced that Michael Babich, former CEO of Insys Therapeutics, agreed to plead guilty to participating in a bribery scheme which gave kickbacks to doctors in exchange for prescribing a powerful opioid painkiller. Babich, who resigned his role as CEO of the Arizona-based drug manufacturing firm, was scheduled to…

Read More

Januvia and Byetta Lawsuits Are Going Back to Court

Januvia and Byetta, along with Janumet and Victoza, are the diabetes drugs at the center of 945 lawsuits. The cases had originally been dismissed, but a federal appeals court overturned that decision in December of 2017, and remanded the cases back to U.S. District Judge Anthony Battaglia in the Southern District of California. He has…

Read More

FDA Issues Warning against Vaginal Rejuvenation Procedures, Citing Potential for Severe Injury

The Food & Drug Administration (FDA) has issued a warning to women who are considering vaginal rejuvenation cosmetic procedures that would use energy-based devices. Per the FDA, “To date, we have not cleared or approved for marketing any energy-based devices” for the procedure. FDA Commissioner Scott Gottlieb made an additional statement about the devices used…

Read More

FDA Recalls Even More Drugs Which Use Valsartan, Citing Cancer Risk

In July of 2018, the Food & Drug Administration (FDA) issued a recall notice for a number of drugs containing valsartan, a medication used in the treatment of high blood pressure and congestive heart failure. The batches, which had been manufactured in China, contained traces of N-nitrosodimethylamine (NDMA) – a cancer-causing carcinogen. In early August,…

Read More